published meta-analysis   sensitivity analysis   studies

anticoagulant, curative dose in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsREMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.08 [0.85; 1.38] 1.08[0.85; 1.38]REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 202110%1,098NAnot evaluable clinical improvementdetailed resultsREMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 0.83 [0.67; 1.03] 0.83[0.67; 1.03]REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 202110%1,074NAnot evaluable Major thrombotic events or deathdetailed resultsREMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.04 [0.80; 1.36] 1.04[0.80; 1.36]REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 202110%1,091NAnot evaluable Major bleedingdetailed resultsREMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.48 [0.74; 2.98] 1.48[0.74; 2.98]REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 202110%1,091NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-03-29 15:57 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 830 - roots T: 290